C-Z3YVEpirium Bio
PGE-2 signaling, oral small molecules, tissue homeostasis
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Z3YV
C-Z3YVC-Z3YVPGE-2 signaling, oral small molecules, tissue homeostasis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.
This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).
On December 16, 2015, PPMD Founding President and CEO, Pat Furlong interviewed Dr. George Schreiner, President and CSO of Cardero Therapeutics, Inc. to discuss the potential benefits of epicatechin to people with Duchenne. It was a fascinating conversation about an all-natural therapy that could benefit the entire Duchenne population, regardless of age or gene mutation. If you would like to support epicatechin and other early-stage research that holds promise for the entire Duchenne community, please consider making a donation to PPMD’s ongoing holiday campaign. All donations made today online will be matched dollar for dollar! http://www.ParentProjectMD.org/EverySingleOne :: About Epicatechin :: The scientists of Cardero Therapeutics have discovered that epicatechin, a member of the flavonoid family of molecules that are found in numerous plants, is the most potent inducer of mitochondrial formation described to date, and appears to exert therapeutic effects on the regeneration of
%PDF-1.7 %���� 1 0 obj >/Metadata 1755 0 R/ViewerPreferences 1756 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Z[o\�~���dzAu���0X��ĉT����f���V�J.�߹� 8�o8��g�d�_mnW_�[q��G�����R*�e�K�������Ã�wgN|�9 EE��W�R�X��k�2V�z� lUo%�GBod !o&�F�/���y� yU&��P6�W�Վ S������(F4��i�Ƿa�O���@� �1�RC���|�(´�_�����N��9m#�tB��'M{vd��/ !����z �� k�(���� ���1m }�-�`83G kqz ���ZE0f���1�3C�j� -�f� �u�B� 3�A�JH���ǖ��jB)cM � … �A�[�C5�g\��s:vM���A�|� v�j��K���a��M]k���c��qO��� � ����C�:zV����`��%����zӧRFP�>ǝx�}F7v�� �H��(��(��JJ ���)3@i(��!���IGz(�4��@Š�f�� ��)���q���Zq� �e8�(�4Hh)(&�M1��4���'&��L���74���1sHM!4��Ni�A4�L�4ozB �74��1���R Fi���2�cQ��&�h$L�Hh�(�SiA���f�4Q�JJu- 4f� HM%�b��L-@�m&i(iȬ�3O������B����Q��� �oSڬ���9>���`t�3֖!�Y骭!㧩�PX�zzT�I� (��t`N9 F�ހ��)*E��b)$����BqQ4�4��Jp:SM1d�i��\b4�i�M�҃����5Iu h��� ƿ� `=?CHznj7QJ ) �䓂>��i���O� ��M�
Epirium Bio Announces Positive Type... - Pharmaceutical Daily Facebook Log In Pharmaceutical Daily's Post Pharmaceutical Daily January 27 · Shared with Public Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia - Alignment gained on Phase 2b inclusion/exclusion criteria, primary and secondary endpoints, and trial design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2b in the second half of 2026 SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc. (Epir
DRS 1 filename1.htm DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 BOUNDLESS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 83-0751369 (State or other jurisdict … ; per share. We intend to apply to list our common stock on the Nasdaq Global Market under the symbol “BOLD,” and this offering is contingent upon obtaining such approval. We are an “emerging growth company” and a “smaller reporting company” as defined under U.S. federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements in this pros … led preclinical cancer models. BBI-825 is currently in investigational new drug application (IND)-enabling studies, and we anticipate submitting an IND to the U.S. Food and Drug Administration (FDA) in 1 Table of Contents , with the potential to initiate a first-in-human, Phase 1/2 clinical trial in patients with ecDNA-enabled cancers thereafter. Our third ecDTx program is d … s, Belharra Therapeutics, and Vividion Therapeutics; recipient of the 2022 Wolf Prize for chemistry; member of the National Academy of Sciences; current member of our Scientific Advisory Board. • Prashant Mali, Ph.D., Professor of Bioengineering at the University of California, San Diego; co-founder of Navega Therapeutics and Shape Therapeutics. • Roel Verhaak, Ph.D., Professor in the Department of Neurosurgery at Yale Unive … gether with our existing cash, cash equivalents, and short-term investments, to fund the research and development of our ecDTx, ecDNA diagnostic test, and Spyglass platform, and for working capital and general corporate purposes. See the section titled “Use of Proceeds.” Risk factors See the section titled “Risk Factors”
Cure SMA Attends Spring 2022 Conferences to Promote Findings from Industry Collaboration Initiatives - Cure SMA Skip to content Shop Latest News About Us Our Story Mission & Vision Our History Our Team & Partners Leadership Local Chapters National Partners Support & Resources Contact Us Community Support Annual Reports & Financials Publications Media SMA About SMA Overview Describing SMA Genetics Testing & Diagnosis Newborn Screening Living with SMA Overview Newly Diagnosed Infants & Children Teens & Adults Traveling with SMA Carriers of SMA Research Study Opp
%PDF-1.7 %���� 1 0 obj >/Metadata 2550 0 R/ViewerPreferences 2551 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Zmoܸ�n������C,�Rhι\�K��.�!�{��1����S����̐�d����I[�pD�g����tsw�i�ߩ��T�9 �X������#Y��l �.���Z�S�,"K:6� � �Cdc ��G/�R� �}� +��?�2Aʈ� #���S;Q��iٻ� 3h�Lf�Cc�J;q ��c��Ocfr ���l��qݲ�RV22��r�����8��⎲?��I�5�F�5���8���b.w݀"� ��g[�Q�3 ��L:��!m��ݨ��c�n�'0C.�lR������ �G��h1� z�8����a�@ ���q[ q���0T���n��=�9i
DRS 1 filename1.htm DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 26, 2026. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kardigan, Inc. (Exact name of registrant as specifie … will be between $    and $   . We intend to apply to list our common stock on     the     under the symbol “KARD.” We believe that upon the completion of this offering, we will meet the standards for listing on the     , and the completion of this offering is contingent upon such listing. We are an “emerging growth company” and “smaller rep … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will 5 Table of Contents not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not … together with our existing cash, cash equivalents and short-term investments to fund the clinical development of Danicamtiv, Ataciguat and Tonlamarsen, to fund other research and development activities, and the remainder for working capital and other general corporate purposes. See the section titled “ Use of Proceeds ” for additional information. Risk factors Investing in our common stock involves a high degree of risk. See the section titled “ Risk … stock options as of December 31, 2025 under our 2023 Stock Option and Grant Plan, as amended (“2023 Plan”), with a weighted average exercise price of $4.36 per share; 7 Table of Contents • 2,059,429 shares of common stock issuable upon exercise of outstanding stock options granted after December 31, 2
Carolyn Ng, Ph.D. - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Careers Contact Our Locations San Diego Great … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc … g Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she co-headed the investment team. Dr. Ng has previously served on the board of directors for other promising public and private life sciences companies including Bicycle Therapeutics PLC (NASDAQ: BCYC), Boundless Bio, Obsidian Therapeutics, 28-7 Therapeutics, Epirium Bio, Nuvaira, and a board observer to Visterra (acquired by Otsuka Pharmaceutical). Carolyn is a mentor to the Women in … the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship. Join About Us Our Team Board of Directors Our Locations Careers Contact Membership Become a Member Member Benefits Community Building Member Login Member Directory Concierge Contract Research Organizations Conferences & Events Upcoming Events Webinar
Calling All Individuals with Becker Muscular Dystrophy – We Need You! - Parent Project Muscular Dystrophy Emergency care guidelines Go About PPMD Events News About Duchenne What is Duchenne? Signs & Symptoms Duchenne Diagnosis Progression Interpreting CK Levels What is Becker? Signs and Symptoms Becker Diagnosis Understanding Genetics Understanding Genetics Types of Genetic Variants Genetic Testing Genetic Counseling Carriers Newborn Screening Newly Diagnosed? What You Need to Know Join the Community Things to Do Now Decode Duchenne Free Genetic Testing Program Care For Families For Newly … recautions Find a Certified Duchenne Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Professionals For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Regulator … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities Drug Development Roundtable Resources Get Involved Donate Make a Donation Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Bad Shirt Friday Advocate Join The Duchenne Registry Connect With the Community Find a Local Connect Group The PAAC: Teens & Adults with Duchenne … sthesia Precautions Find a Certified Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Providers For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Advocacy Regu … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities PPMD’s Drug Development Roundtable Resources Get Involved Donate Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Advocate Join the Duchenne
Treating Fibrosis and Oxidative Stress - TREAT-NMD Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer TREAT-NMD Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world Contact us header-right Home Who We Are About Us Partnerships and Collaborations Our Team Who We Support Patients Clinicians / Researchers Life Sciences Industry What We Do Advisory Committee for Therapeutics The Global Registry Network Core Datasets Education Post-Marketing Surveillance Resources and Support Neuromuscular Disease Information Research Ov … e Committee Abstracts Venue News & Events News TREAT-NMD Events All Events Submit an Event Newsletter Sign-up Contact Us Treating Fibrosis and Oxidative Stress Home / Resources and Support / Research Overview / DMD / Drug Therapy / Treating Fibrosis and Oxidative Stress Treating Fibrosis and Oxidative Stress Current status: clinical trials ongoing with various anti-fibrotic compounds Chronic inflammation results in fibrosis (scar tissue formation) and adipose tissue (fat … reated patients at the time of filing and therefore cannot consider the current application. In 2017 and 2018 the Committee for Human Medicinal Products gave a negative opinion on the use of Idebenone for DMD. In May 2019 Santhera filed for conditional marketing authorization with EMA for the treatment of respiratory dysfunction. However, in October 2020 Santhera announced they stopped the phase 3 clinical trial as an interim an … endpoint would not be met. They then also withdrew the marketing authorization application from EMA. Pentoxifylline Pentoxifylline has been tested in a clinical trial and was found not to slow down disease progression and was poorly tolerated by patients. Flavocoxid is another antioxidant that has been tested in a phase 1 trial in Duchenne patients to assess safety. Primary Sidebar Resources and Support Disease Information Neuromuscular Di … mittee Abstracts Venue Back News & Events News TREAT-NMD Events All Events Submit an Event Newsletter Sign-up Contact Us Back × Close Panel
Skip to Content In the Pipeline: Downstream Targets Archives - Parent Project Muscular Dystrophy Emergency care guidelines Go About PPMD Events News About Duchenne What is Duchenne? Signs & Symptoms Duchenne Diagnosis Progression Interpreting CK Levels What is Becker? Signs and Symptoms Becker Diagnosis Understanding Genetics Understanding Genetics Types of Genetic Variants Genetic Testing Genetic Counseling Carriers Newborn Screening Newly Diagnosed? What You Need to Know Join the Community Things to Do Now Decode Duchenne Free Genetic Testing Program Care For Families For Newly Diagnose … recautions Find a Certified Duchenne Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Professionals For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Regulator … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities Drug Development Roundtable Resources Get Involved Donate Make a Donation Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Bad Shirt Friday Advocate Join The Duchenne Registry Connect With the Community Find a Local Connect Group The PAAC: Teens & Adults with Duchenne … sthesia Precautions Find a Certified Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Providers For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Advocacy Regu … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities PPMD’s Drug Development Roundtable Resources Get Involved Donate Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Advocate Join the Duchenne
About — Catalytic Impact Foundation 0 Skip to Content Home Who We Are About Us Team Foundation Advisors Ways to Give Impact Reports 2025 Impact Report 2024 Impact Report 2023 Impact Report Our Work Women's Health Initiative Children's Health Initiative Portfolio Portfolio Companies News & Events Portfolio Company News Press & Media Contact Fiscal Sponsorship Donate Open Menu Close Menu Home Who We Are About Us Team Foundation Advisors Ways to Give Impact Reports 2025 Impact Report 2024 Impact Report 2023 Impact Report Our Work Women's Health Initiative Children's Health Initiativ … ibe/simvastatin). He is the recipient of the 2005 National Inventor of the Year Award, the American Chemical Society’s 2004 Heroes of Chemistry Award. He is currently a Senior Research Fellow in the College of Letters and Sciences at the University of California, Davis, and was as a Trustee on the UC Davis Foundation Board. He is a co-author of more than 70 publications and presentations, and a co-inventor of over 100 issued and applied patents. He earned his Ph.D. from the U
Sarcopenia Development Council | Epirium Bio Sarcopenia Development Council – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Sarcopenia Development Council David Cella, Ph.D. Director, Institute for Public Health and Medicine Center for Patient-Centered Outcomes Northwestern University Feinberg School of Medicine David Cella, Ph.D. Di
Careers | Epirium Bio Careers – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Careers There are no current job openings Epirium Bio and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. We do not ask candidates to purchase anything through us or to provi
Careers | Epirium Bio Careers – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Careers There are no current job openings Epirium Bio and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. We do not ask candidates to purchase anything through us or to provi
You need to enable JavaScript to run this app. Loading...
Russell J. Cox - President & CEO at Epirium | The Org Platform Enrich Pricing Log in Sign up Epirium Russell J. Cox Unverified Russell J. Cox President & CEO Contact Prior to his role as President and Chief Executive Officer of Epirium Bio, Russell J. Cox served as Chief Executive Officer at Vital Therapies, Inc. He previously served as the Executive Vice President and Chief Operating Officer of Jazz Pharmaceuticals plc, with responsibility for global commercial activities, R&D, manufacturing/technical operations, new product planning and global molecule leadership. Prior to Jazz
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Epirium Bio: Funding, Team & Investors | Startup Intros Home / Organizations / Epirium Bio § … eries A — ARCH Venture Partners , Adams Street Partners , Jeff Bird , Longevity Fund , Patrick Enright , Vertex Ventures HC Announced Deep Dive High-Level Overview Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics that inhibit 15-PGDH to elevate PGE2 levels, promoting mitochondrial biogenesis, muscle regeneration, and tissue repair for neuromuscular and neurodegenerative diseases.[1][2][4] It targets unmet nee … investors including Arch Venture Partners, Longitude Capital, and The Longevity Fund, Epirium demonstrates growth through IP-protected platforms, 19 patents, and advancing clinical programs amid rising demand for muscle rejuvenation therapies.[3][4][7] Origin Story Epirium Bio, based in San Diego, California, traces its roots to 2008 as Cardero Therapeutics before rebranding to focus on its current platform; it formally advanced as a clinical-stage entity around 2017 with fou … ience-driven founding), Longitude Capital (growth-stage biotech), and Longevity Fund (aging-focused), enabling pipeline expansion.[3][7] Role in the Broader Tech Landscape Epirium rides the wave of mitochondrial medicine and longevity biotech , targeting cellular energy deficits underlying age-related muscle loss (sarcopenia affecting 50M+ globally) and rare neuromuscular disorders amid a $100B+ neuromuscular market.[2][3][4] Timing aligns with aging populations, post-2020 in … tors include ARCH Venture Partners, Adams Street Partners, Jeff Bird, Longevity Fund, Patrick Enright, Vertex Ventures HC.
Understanding the Potential of Epicatechin (December 2015) - Parent Project Muscular Dystrophy Emergency care guidelines Go About PPMD Events News About Duchenne What is Duchenne? Signs & Symptoms Duchenne Diagnosis Progression Interpreting CK Levels What is Becker? Signs and Symptoms Becker Diagnosis Understanding Genetics Understanding Genetics Types of Genetic Variants Genetic Testing Genetic Counseling Carriers Newborn Screening Newly Diagnosed? What You Need to Know Join the Community Things to Do Now Decode Duchenne Free Genetic Testing Program Care For Families For Newly Diagnosed … recautions Find a Certified Duchenne Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Professionals For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Regulator … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities Drug Development Roundtable Resources Get Involved Donate Make a Donation Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Bad Shirt Friday Advocate Join The Duchenne Registry Connect With the Community Find a Local Connect Group The PAAC: Teens & Adults with Duchenne … sthesia Precautions Find a Certified Care Center Certified Duchenne Care Center Application Access & Coverage Resources For New Therapies For Medical Equipment Support & Care Materials Webinar & Video Library PPMD For You: Schedule a One-To-One Meeting for Personalized Support For Adults / Young Adults For Carriers For Healthcare Providers For Educators Our Strategy & Impact Advocacy Our Strategy & Impact Legislation & Public Policy Advocacy Regu … Venture Pathways For Researchers & Industry Recruit for Research Research Grant Opportunities PPMD’s Drug Development Roundtable Resources Get Involved Donate Matching Gifts Find Sponsorship Opportunities PPMD Merchandise Fundraise Race to End Duchenne DIY Fundraising Coach To Cure MD World Duchenne Awareness Day Advocate Join the Duchenne
%PDF-1.5 %���� 3258 0 obj > endobj xref 3258 85 0000000016 00000 n 0000007591 00000 n 0000007708 00000 n 0000009401 00000 n 0000009440 00000 n 0000009555 00000 n 0000009670 00000 n 0000014138 00000 n 0000019155 00000 n 0000024110 00000 n 0000029262 00000 n 0000029801 00000 n 0000030280 00000 n 0000030871 00000 n 0000036646 00000 n 0000042749 00000 n 0000043298 00000 n 0000043404 00000 n 0000043925 00000 n 0000044545 00000 n 0000049762 00000 n 0000055295 00000 n 0000057946 00000 n 0000061903 00000 n 0000066242 00000 n 0000100333 00000 n 0000100374 00000 n 0000134023 00000 n 0000134064 00000 n 0 … hg"4%%5��u�F^�=��S\\x�@gE/� ��a�J:��(ȃA��4 �7:�����8�=ar wə�����q >stream application/pdf conference-cover2 Adobe Illustrator 26.2 (Windows) 2022-05-19T11:58:04-05:00 2022-05-19T11:58:06-05:00 2022-05-19T11:58:06-05:00 uuid:9E3E5C9A8C81DB118734DB58FDDE4BA7 xmp.did:78c77570-ea36-e943-a870-20b830e4bb17 uuid:2e8ebd63-2e47-496f-8d73-8eff4bd99dea proof:pdf uuid:6c1ca68e-13b6-478a-acc7-cd82048d2e88 xmp.did:fc533e69-28ed-454e-845c-2ac68ebc0de5 uuid:9E3E5C9A8C81DB118734DB58FDDE … Adobe PDF library 16.04 endstream endobj 3283 0 obj > endobj 3284 0 obj >stream application/pdf conference-cover Adobe Illustrator 26.0 (Windows) 2021-11-24T14:04:16-05:00 2021-11-24T14:04:17-06:00 2021-11-24T14:04:17-06:00 uuid:9E3E5C9A8C81DB118734DB58FDDE4BA7 xmp.did:fc533e69-28ed-454e-845c-2ac68ebc0de5 uuid:6c1ca68e-13b6-478a-acc7-cd82048d2e88 proof:pdf uuid:ec420d7c-bf13-45ff-96db-e40fefc865d4 xmp.did:cf9378d7-5d4b-0d48-bd93-50f01d05ba5b uuid:9E3E5C9A8C81DB118734DB58FDDE4 … Adobe PDF library 16.03 endstream endobj 3285 0 obj > endobj 3286 0 obj >stream application/pdf conference-cover Adobe Illustrator 26.0 (Windows) 2021-11-24T14:04:16-05:00 2021-11-24T14:04:17-06:00 2021-11-24T14:04:17-06:00 uuid:9E3E5C9A8C81DB118734DB58FDDE4BA7 xmp.did:fc533e69-28ed-454e-845c-2ac68ebc0de5 uuid:6c1ca68e-13b6-478a-acc7-cd82048d2e88 proof:pdf uuid:ec420d7c-bf13-45ff-96db-e40fefc865d4 xmp.did:cf9378d7-5d4b-0d48-bd93-50f01d05ba5b uuid:9E3E5C9A8C81DB118734DB58FDDE4 … Adobe PDF library 16.03 endstream endobj 3287 0 obj > endobj 3288 0 obj >stream application/pdf CureSMA_Logo_White 2018-05-04T10:01:26-05:00 2018-05-04T10:01:26-05:00 2018-05-04T10:01:26-05:00 Adobe Illustrator CC 22.1 (Windows) uuid:41fb139e-a9a9-435d-87df-0fc5afd5c862 xmp.did:9b0ef2c7-82a1-2e4c-bc7d-6cf833c3bfc9 uuid:5D20892493BFDB11914A8590D31
%PDF-1.6 %���� 451 0 obj > endobj 473 0 obj >/Filter/FlateDecode/ID[ ]/Index[451 29]/Info 450 0 R/Length 106/Prev 2556265/Root 452 0 R/Size 480/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� Y ��3�d�"�LA$O � ���d4����`r����ցH~ɘ,b����(u�HR���$�u�20120�E�6c!�30Z�0+"? endstream endobj startxref 0 %%EOF 479 0 obj >stream h��U�Og�J� `������R��X���.1Tۂ-Z�8>�d����VVKp�u�#��@,�ò�ZY$� g6K,�M7�Df����[���]�����{���{�ry8 w��|�@*;K[&lH�����)&���r�Ts��QPxR���T�~n:���k.�;���Dj��y9 ���#Њ �� ����X��+��a�fR{�ΠC?|&KjU�$���*�$ƌ���v�ţ�%w���ES���]hI7/�S���)�o ���#td�9~$-�{�C�: … ��5k��yݭ���ǯg��^y�kEk�����l�D_p߶������7Dm����o꿻1m��l�{��Mś� n�L�l� >stream application/postscript PPMD_final_logo_temp coltrane Adobe Illustrator CS3 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 uuid:A3FFA4B6AD34DD11817B8673AE464B67 uuid:A4FFA4B6AD34DD11817B8673AE464B67 uuid:A2FFA4B6AD34DD11817B8673AE464B67 uuid:519D46579534DD11817B8673AE464B67 Print 1 False False 612.000000 792.000000 Points Default Swatch Group 0 White RGB PROCESS 255 2 … 55 255 R=35 G=31 B=32 1 RGB PROCESS 35 31 32 endstream endobj 465 0 obj >stream application/postscript PPMD_final_logo_temp coltrane Adobe Illustrator CS3 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 uuid:A3FFA4B6AD34DD11817B8673AE464B67 uuid:A4FFA4B6AD34DD11817B8673AE464B67 uuid:A2FFA4B6AD34DD11817B8673AE464B67 uuid:519D46579534DD11817B8673AE464B67 Print 1 False False 612.000000 792.000000 Points Default Swatch Group 0 White RGB PROCESS 255 2 … 55 255 R=35 G=31 B=32 1 RGB PROCESS 35 31 32 endstream endobj 466 0 obj >stream application/postscript PPMD_final_logo_temp coltrane Adobe Illustrator CS3 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 2008-06-05T16:22:34-04:00 uuid:A3FFA4B6AD34DD11817B8673AE464B67 uuid:A4FFA4B6AD34DD11817B8673AE464B67 uuid:A2FFA4B6AD34DD11817B8673AE464B67 uuid:519D46579534DD11817B8673AE464B67 Print 1 False False 612.000000 792.000000 Points Default Swatch Group 0 White RGB PROCESS 255 2 … j��j�fI� ���;�J},�E�u�0��%��m�P��9��� 0�_� endstream endobj 3 0 obj >stream application/postscript Print Stephanie Matthes 2015-05-12T16:20:28-04:00 2015-05-12T16:20:28-04:00 2015-05-12T16:20:28-04:00 Adobe Illustrator CC 2014 (Macintosh) xmp.iid:655d7120-5617-43c4-bf79-04105ad47fbf xmp.did:655d7120-5617-43c4-bf79-04105ad47fbf uuid:5D20892493
Stanford University’s 6th Annual Neuromuscular Conference: Evaluating Bulbar Function in the Era of Disease Modifying Treatments - Stanford Center for Continuing Medical Education - Continuing Education (CE) <br>There is a critical need for continuing medical education of health-care providers caring for individuals with NM disease to address the unmet needs in this population.&nbsp; This conference will support the advancement of assessing bulbar function in children and adults by a variety of health professionals with expertise in this area and establish a foundation of evidence-based … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … is activity. Complete the STAP Reimbursement Request Form and submit to your department administrator. Credits AMA PRA Category 1 Credits™ (7.75 hours), ANCC Contact Hours (7.75 hours), Non-Physician Participation Credit (7.75 hours) Target Audience Specialties - Neurology , Occupational Therapy, Pediatrics, Physical Therapy, Speech Language Pathology Professions - Advance Practice Nurse (APN), Fellow/Resident, Non-Physician, Nurse, Occupational … courtesy, Pathology Stanford University Medical Center Course Director, Faculty Grant or research support-Astellas (Relationship has ended)|Grant or research support-CureSMA|Grant or research support-Muscular Dystrophy Association|Grant or research support-AnnJi (Relationship has ended)|Grant or research support-NMD Pharma|Grant or research support-Biogen|Grant or research support-Ionis Pharmaceuticals|Grant or research support-Novartis Gene Therapies|Grant or research suppor … ant or research support-Novartis Gene Therapies|Grant or research support-Roche|Grant or research support-Sarepta Therapeutics|Grant or research support-Scholar Rock|Grant or research support-AMO Pharma|Grant or research support-Avidity Biosciences|Grant or research support-Sanofi-Genzyme|Membership on Advisory Committees or Review Panels, Board
Attendee List | Scope Summit 2026 | February 2-5, 2026 Agenda Programs Search Agenda Keynotes Workshops/User Groups Therapeutic Area Spotlights Participant Engagement Award Site Innovation Award Best of Show Awards Brochures (PDFs) Track Summaries Social Media Wall Archives Venture/Partner Event Venture, Innovation & Partnering Brochure (PDF) Photo Album Faculty/Attendee Attendee List Faculty & Bios FAQ - How to Succeed at SCOPE Meet The Team Attendee Profile & Testimonials Photo Album Speaker Portal Share Your Attendance on Social Media Sponsor/Exhibitor Attendee Demographics and … Therapy PRE-CON EVENTS ◆ Monday Golf ◆ Kickoff Keynote ◆ Participant Engagement Award ◆ SCOPE’s Kickoff Reception ◆ Pre-Con User Group & Workshops 250 First Avenue, Suite 300 Needham, MA 02494 P: 781.972.5400 F: 781.972.5425 E: [email protected] Life Science Portals Biological Therapeutic Products Biomarkers & Diagnostics Biopharma Strategy Bioprocess & Manufacturing Chemistry Clinical Trials & Translational Medicine Drug & Device Safety Drug Discov
Industry - SCWD Skip to content No results Replay: Annual Conference 2025 About the SCWD Society Scientific Board Get a Membership Annual Conference 18th International Conference 2025 Abstract Submission 2025 Programme 2025 Congress Information 2025 SCWD Virtual 2025 Past events SCWD Publications Digest Guidelines Videos Contact Shopping Cart Your cart is currently empty. Return to shop Username or Email Address Password Remember Me Forgot Password? Log In Username or Email Address Get New Password ← Back to login ➜ Journal of Cachexia, Sarcopenia and Muscle Shopping cart Free 0 Login No resul … eaders, engage in insightful discussions, and expand your professional network. Submit an Abstract 2026 ⟶ Are you ready to share your groundbreaking research and innovative ideas with leading experts in the field? We invite you to submit your abstract for the 2026 conference. Resources Resources Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Nutrition ↗ From the Literature ↗ Cancer Cach
Epirium Bio | Vertex Ventures HC Job Board Vertex Ventures HC Portfolio Careers Discover opportunities across our network of portfolio companies. • jobs · • companies Search jobs Explore companies Join talent network Talent My job alerts Epirium Bio epirium.com Locations San Diego, CA, USA · Liberty Station, San Diego, CA, USA industry Biopharma · Biotechnology · Health Care · Pharmaceutical Manufacturing · Therapeutics Size 11 - 50 employees Stage Series A founded in 2008 Socials LinkedIn Crunchbase About Epirium Bio is a biopharmaceutical company based in San Diego. It is developing a small
18th SCWD International Conference: Sarcopenia, Cachexia & Wasting Disorders Skip to content No results Replay: Annual Conference 2025 About the SCWD Society Scientific Board Get a Membership Annual Conference 18th International Conference 2025 Abstract Submission 2025 Programme 2025 Congress Information 2025 SCWD Virtual 2025 Past events SCWD Publications Digest Guidelines Videos Contact Shopping Cart Your cart is currently empty. Return to shop Username or Email Address Password Remember Me Forgot Password? Log In Username or Email Address Get New Password ← Back to login ➜ Journal of Ca … eaders, engage in insightful discussions, and expand your professional network. Submit an Abstract 2026 ⟶ Are you ready to share your groundbreaking research and innovative ideas with leading experts in the field? We invite you to submit your abstract for the 2026 conference. Resources Resources Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Nutrition ↗ From the Literature ↗ Cancer Cach … aking place in Washington, USA , from December 10-12, 2026. Abstract submission deadline is August 31, 2026. Additional information will be available in the upcoming months on the website. The SCWD Board is committed to providing an exceptional experience that meets the needs of our global community. The conference aims to: Foster in-person connections and collaboration among the cachexia and sarcopenia communities; Share the latest advancements in research and treatment; Off
Epirium Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 13 Apr 2026 Epirium Bio, Inc. Startups | Holding Company | 2008 | California, United States | 10-50 | www.epirium.com Startups | Holding Company | 2008 | California, United States | 10-50 | www.epirium.com Last update 13 Apr 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Respiratory Diseases Small molecule drug Disease domain score A glimpse into … elated sarcopenia in the second half of 2026. The Company also plans to file an application for Fast Track Designation which, if accepted, will allow greater access to FDA interaction during MF-300 development for sarcopenia and enable priority review. “We are pleased with the positive outcome of our End-of-Phase 1 meeting with the FDA, which provided constructive guidance on our development strategy for MF-300 in sarcopenia,” said Alex Casdin, Chief Executive Officer of Epir … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
(-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy (-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy Muscle Nerve . 2021 Feb;63(2):239-249. doi: 10.1002/mus.27108. Epub 2020 Dec 16. Authors Craig M McDonald 1 , Israel Ramirez-Sanchez 2 3 , Björn Oskarsson 4 , Nanette Joyce 1 , Candace Aguilar 1 , Alina Nicorici 1 , Jonathan Dayan 1 , Erica Goude  
Epirium Bio - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Epirium Bio Catechins to stimulate mitochondrial biogenesis. Website Profile prev next Website Bookmark Share prev next General Headquarters San Diego, California, United States Founders & Team George Schreiner, Sundeep Dugar, Russell Cox Year Founded 2017 Company type Private company Funding stage Series A Total funding ($M) 85 Investors The Longevity Fund
George Schreiner - Chief Scientific Officer at Epirium | The Org Platform Enrich Pricing Log in Sign up Epirium George Schreiner Unverified George Schreiner Chief Scientific Officer Contact Dr. Schreiner was the founding Chief Executive Officer/President of Epirium Bio and currently serves as the Chief Scientific Officer. His career has been grounded in basic and clinical biomedical science, drug development and corporate strategic development. After serving on the faculty at Harvard Medical School and the University of Washington School of Medicine, he was a founding scientist and vice pres
Cardero Therapeutics, Inc. Form D Filings Cardero Therapeutics, Inc. Form D Filings Location Sunnyvale, CA Industry Group Other Related People George Schreiner , Sundeep Dugar , Alan Maisel , Julian Buckner , Barry Dickman Entity Type Corporation CIK 0001532510 All SEC Filings View on sec.gov Date Filed Security Types Total Amount Sold Total Offering Amount Remaining First Sale Signed Form SEC Link 10/16/2014 Equity, Other $891,999 $1,500,000 $608,001 10/3/2014 10/15/2014 D 000128864914000008 10/13/2011 Equity $1,000,000 $10,300,000 $9,300,000 9/29/2011 10/13/2011 D 000153251011000001 All Mana
US20190046517A1 - Methods and compositions for treatment of mitochondrial toxicity - Google Patents US20190046517A1 - Methods and compositions for treatment of mitochondrial toxicity - Google Patents Methods and compositions for treatment of mitochondrial toxicity Download PDF Info Publication number US20190046517A1 US20190046517A1 US16/107,426 US201816107426A US2019046517A1 US 20190046517 A1 US20190046517 A1 US 20190046517A1 US 201816107426 A US201816107426 A US 201816107426A US 2019046517 A1 US2019046517 A1 US 2019046517A1 Authority US United States Prior art keywords epicatechin mitochondri … s and makes no representation as to the accuracy of the status listed.) Granted Application number US16/107,426 Other versions US20200155533A9 ( en US11154546B2 ( en Inventor Francisco Villarreal Alan Maisel George SCHREINER Guillermo M.Ceballos REYES Pam Taub Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Epirium Bio Inc Original Assignee Cardero Ther … sted.) 2011-06-06 Filing date 2018-08-21 Publication date 2019-02-14 2018-08-21 Application filed by Cardero Therapeutics Inc filed Critical Cardero Therapeutics Inc 2018-08-21 Priority to US16/107,426 priority Critical patent/US11154546B2/en 2019-02-14 Publication of US20190046517A1 publication Critical patent/US20190046517A1/en 2020-05-21 Publication of US20200155533A9 publication Critical patent/US20200155533A9/en 2021-10-26 Application granted granted Critical 2021-10-26 … is fully defined in groups A61K31/00 - A61K41/00 Definitions the present patent application relates to treatment and prevention of acute injuries, and prevention or reversal of states of chronic mitochondrial depletion or dysfunction. Mitochondria are specialized compartments present in cells that are responsible for creating more than 90% of the energy needed by the body to sustain life and support growth. When mitochondrial function fails, less energy is generated within th … food, or drug. Description CROSS REFERENCE TO RELATED APPLICATIONS The present application claims priority to U.S. Provisional Patent Application No. 61/493,932 filed Jun. 6, 2011, which is hereby incorporated in its entirety including all tables, figures, and claims. BACKGROUND The following discussion of the background of the invention is mere
Epirium Bio - The Pill Built to Fight Muscle Loss Breaking MF-300 clears Phase 1 - generally well tolerated in healthy volunteers FDA supports advancement to a Phase 2b trial in sarcopenia $85M Series A co-led by Longitude Capital and ARCH Venture Partners Up to 1 in 3 Americans over 60 are affected by sarcopenia Zero FDA-approved therapies exist for age-related muscle loss First-in-class oral 15-PGDH inhibitor Phase 2b expected in the second half of 2026 San Diego · Clinical-Stage Biopharma Epirium Bio Turning the body's own repair signal into a pill for the muscle loss that comes with … Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund joining. Then, in a move that says something about how the company sees its next chapter, it brought in leadership from the operating and investing worlds: Russell Cox, formerly of Jazz Pharmaceuticals, and later Alex Casdin, a healthcare investor who took the CEO seat in 2025. The clever part isn't the drug you add. It's the enzyme you take away. - The 15-PGDH thesis, compressed The product … linic. December 2024 FDA clears the IND for MF-300 The Investigational New Drug application is cleared; Alex Casdin is named incoming CEO and Russell Cox becomes Executive Chairman. September 2025 Positive Phase 1 results MF-300 is generally well tolerated across all doses in healthy volunteers, with dose-related pharmacodynamic responses observed. Late 2025 / Early 2026 Positive FDA Type C meeting The FDA supports advancing MF-300 to a Phase 2b trial in sarcopenia; new clini
%PDF-1.7 %���� 1 0 obj >/Metadata 2306 0 R/ViewerPreferences 2307 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Z[o�~7����B��c��Y�u⦨7i��>h'r"��*J���=�ñ��3v�"���� y�����z��\t�����=)d#�TZ� Z/��R���{��I��� ��;������ ��J7��i� �{� �z8Xc �� T�Q�:yզ���}��l�u�R��;�H1g��=��Ѫ�=���D1���DC��_���̡q��]����J�Ux 5öG ��SԒ-�(��z�� =M:���l��ݨ�_c�cCEM�o(�5n� ����(��0����`f�!b6�W�&G�Q�� ���q� ���3�E�����9� d���� I �Jb@��hbH\�+a�� օt … �A�[�C5�g\��s:vM���A�|� v�j��K���a��M]k���c��qO��� � ����C�:zV����`��%����zӧRFP�>ǝx�}F7v�� �H��(��(��JJ ���)3@i(��!���IGz(�4��@Š�f�� ��)���q���Zq� �e8�(�4Hh)(&�M1��4���'&��L���74���1sHM!4��Ni�A4�L�4ozB �74��1���R Fi���2�cQ��&�h$L�Hh�(�SiA���f�4Q�JJu- 4f� HM%�b��L-@�m&i(iȬ�3O������B����Q��� �oSڬ���9>���`t�3֖!�Y骭!㧩�PX�zzT�I� (��t`N9 F�ހ��)*E��b)$����BqQ4�4��Jp:SM1d�i��\b4�i�M�҃����5Iu h��� ƿ� `=?CHznj7QJ ) �䓂>��i���O� ��M�
Epirium Bio Advances MF-300 in Phase 2b Sarcopenia Trial | Epirium Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
%PDF-1.7 %���� 1 0 obj >/Metadata 2265 0 R/ViewerPreferences 2266 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Z�n �}����"n�Nv`��k�A�M"yX�Ai˶KV�����SE��%MKn�@`X3�XM֍UE� ���>�p2\���~T����JwZkc�N��Z�����~P�{o�������Q ��F�0����������O4��l�%D�?��K&���{����p���$��H���L�>���9 !w.���{!uɘ�����:�܄0�����{���c��םuSyoRg�T�F�Oz[�{]4�)���Gv��m�t�|�J=�ްb�u)F�!ª�#!��e���� ������&�w 0�.8�^ �U1v���(��+��l�>&䠢� ��'*���}�����a���F ����5� … �A�[�C5�g\��s:vM���A�|� v�j��K���a��M]k���c��qO��� � ����C�:zV����`��%����zӧRFP�>ǝx�}F7v�� �H��(��(��JJ ���)3@i(��!���IGz(�4��@Š�f�� ��)���q���Zq� �e8�(�4Hh)(&�M1��4���'&��L���74���1sHM!4��Ni�A4�L�4ozB �74��1���R Fi���2�cQ��&�h$L�Hh�(�SiA���f�4Q�JJu- 4f� HM%�b��L-@�m&i(iȬ�3O������B����Q��� �oSڬ���9>���`t�3֖!�Y骭!㧩�PX�zzT�I� (��t`N9 F�ހ��)*E��b)$����BqQ4�4��Jp:SM1d�i��\b4�i�M�҃����5Iu h��� ƿ� `=?CHznj7QJ ) �䓂>��i���O� ��M�
Piramal Pharma Solutions to Collaboratewith Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs --> --> --> --> --> --> --> --> --> --> --> --> --> --> Close --> Facebook Linkedin Twitter Youtube Home News Articles Press Releases Events Reports BioPharma Nutraceutical More Contact Us Interviews White Papers Newsletter Archive Target Audience Magazine Issues Testimonials Search Home Magazine Videos Gallery Newsletters Media Packs Advertise Sign in Welcome! Log into your account your username your password Forgot your password? Get help Privacy Policy Pas … the Terms and conditions and the Privacy policy Please enable the javascript to submit this form Media Packs Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! – Access the Media Pack Now – Book a Conference Call – Leave Message for Us to Get Back Related stories Business & Industry Merck KGaA to Acquire Bio-Techne for $11.3 Billion to Bolster Life Science Division The German pharmaceutical group Merck KG … the Terms and conditions and the Privacy policy Please enable the javascript to submit this form Media Packs Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! – Access the Media Pack Now – Book a Conference Call – Leave Message for Us to Get Back Clinical Trials Drug Research IT & Data Management Packaging & Labelling Home News Articles Press Releases Interviews White Papers Industry Reports About us … tem Sitemap RSS Feed Privacy Policy RESOURCES Target Audience Advertise With Us Submit Your Events Media Pack Contact Us ARCHIVE LINKS Newsletter Archive Print Issues Search Subscribe I agree with the Terms and conditions and the Privacy policy Please enable the javascript to submit this form Copyright © 2010- 2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd. Translate » Cookie Consent We use cookies to improve your experience on our site. By us
%PDF-1.3 %��������� 4 0 obj > stream x��ms�Fr��燎)R\J���=�h�g[��|g_�ʋ0/R*�.);����ϯ�{�3�� � ����~�wOπ�{�C����������.���L������*~�����?��?�Z ~-J��� x��խ��/C��kH }×��|��xx,���b �?���UQ��Vl����?�/ '1���Kr���k��0�ܕU�/ ?���(��\l?;�*�b�� �������E��w�-�q�"� e�R��Y�FWW�j�&�@��j�RnW7�C{��ܡ��P�ic��&m\>m����N*X�`�t�� �*ج9�W��U�#�� ������튾��C���N߫��#�9@�b ��.z���Ն�#���S�`���� V���kF1�4 �fNN$��$��$O[�U Y@�W��kw���z� �qX��U)���:��}�OR�@�:�-u�톦�Ϲ�t.K����e(��]S�s�9z����; Ü��o�+�ƻ�h}�-�����6����&.�x�m���7�r�Oen-���B���簚�ð�W �G�� �\} U�Lߚ� � mUJHt���zE�E��y8;�R��ӕ����%�%
%PDF-1.7 %���� 1 0 obj >/Metadata 1993 0 R/ViewerPreferences 1994 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Z�o77������^�� �4M�Cݦ�}�ރ�(�p������o>H.���Jw��� g��̏�!W�/�����Žxu����D �J)��2��K����ɯ߈�ӓ� .��twz�ħ�,����h������=�z�3�R�_��[��6*+��- ��.�Ƌ��ڠԐ@�:� ��S v;�g�w�جjl ���l����ZZ���`��G�?�1���E��Og9ʙ6x}z��xݚ(�Т� ��b�}U�B��:�����V%�):�t}���!T�m �^�J9@�c�V�.P�]k0��j�Dzt��,!�M�ψ��Q���/#�!�ʂl ��F��׳c�B��)x#� … �A�[�C5�g\��s:vM���A�|� v�j��K���a��M]k���c��qO��� � ����C�:zV����`��%����zӧRFP�>ǝx�}F7v�� �H��(��(��JJ ���)3@i(��!���IGz(�4��@Š�f�� ��)���q���Zq� �e8�(�4Hh)(&�M1��4���'&��L���74���1sHM!4��Ni�A4�L�4ozB �74��1���R Fi���2�cQ��&�h$L�Hh�(�SiA���f�4Q�JJu- 4f� HM%�b��L-@�m&i(iȬ�3O������B����Q��� �oSڬ���9>���`t�3֖!�Y骭!㧩�PX�zzT�I� (��t`N9 F�ހ��)*E��b)$����BqQ4�4��Jp:SM1d�i��\b4�i�M�҃����5Iu h��� ƿ� `=?CHznj7QJ ) �䓂>��i���O� ��M�
%PDF-1.7 %���� 1 0 obj >/Metadata 92 0 R/ViewerPreferences 93 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\[o��~7��0�R��r� ^څۻ R h�l����DY�ʲBR븿��;ëH:�w�]K"9�̹߆����Ç�?���Q������x�ï��+���8?�p ���ZF�?�*TZR�0V"O��~�Nl�Ϥ ��� �C� �A9Q$��g��O�R->>�_��ħ�n�耗x�j��1qG@]�ž�BJ����g�R��q�/B7v4]!������5� ����gb� �� �g�h�1T�=T�8 *4� ��g�H9A�b �b��� � �|�ͽY6��f9��O��Գ�>j߂�tC��&�؉'Ao|�`���:{�T�N��bw*� @��/�Y����>���Y)�j��� ɟ� X!�;
Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Management Team & Advisors | Epirium Bio Management Team & Advisors – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Management Team & Advisors Management Team Alexander Casdin Chief Executive Officer Alexander Casdin Chief Executive Officer Alex is Epirium’s Chief Executive Officer, and a member of the board of directo … olio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the D
Epirium presents positive Phase 1 results for MF-300 at GSA Meeting | Alexander Casdin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … Nobel Prizes were awarded. The scientific breakthroughs celebrated by the Nobel Prize over the years have shaped modern medicine and scientific discovery. Click through our post to learn more about the first Nobel Prizes and their impact on the scientific community. Genemarkers supports the next generation of scientific progress through high-quality molecular testing solutions for preclinical, translational, and clinical research. Learn more about Genemarkers: https://lnkd.in
Presentations | Epirium Bio Presentations – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Presentations June 2026 Epirium Bio Non Confidential Deck For Clinical Study Inquiries, please contact [email protected] For additional information, please contact [email protected] ©2026 Epirium Bio
BIOCOM Diagnostics - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 BIOCOM Diagnostics Private Company | South Africa | www.biocomdiagnostics.co.za Private Company | South Africa | www.biocomdiagnostics.co.za Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with BIOCOM Diagnostics Login to view more data 0 Patents (Medical) associated with BIOCOM Diagnostics Login to view more data 32 New … of science in physics from Georgetown University. She completed a postdoctoral fellowship at Cornell Medical College supported by the NIH Kirschtein National Research Service Award. Carolyn Ng, Ph.D. is a business unit partner at TPG Life Sciences Innovations, where she is one of the founding senior leaders of the investment fund. She has spent the past decade of her career leading investments into transformative companies of early to mid-stage in different therapeutic areas … g director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she co-headed the investment team. Dr. Ng has previously served on the board of directors for other promising public and private life sciences companies including Bicycle Therapeutics PLC, Boundless Bio, Obsidian Therapeutics, 28-7 Therapeutics, Epirium Bio, Nuvaira and a board observer to Visterra (acquired by Otsuka Pharmaceutical). Dr. Ng is a mentor to the Women in Bio Boardroom Re … he recipient of the prestigious NGS, Integrative Sciences and Technology, Ph.D. scholarship, and patent holder of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma. Nancy Whiting, Pharm.D. is a president and CEO at Recludix Pharma. Previously, Dr. Whiting was a 15-year veteran of Seagen, formerly Seattle Genetics, and served as the executive vice president of corporate strategy, where she had the broad remit of corporate strategy a … d received her Pharm.D. from the University of Washington. She also completed a residency in clinical pharmacy practice at Vancouver General Hospital. About Biocom California Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,800 members to drive public policy , build an enviable ne
Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Investors | Epirium Bio Investors – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Investors ARCH follows the science to found companies based on revolutionary technologies that can impact people’s lives and take a long-term view when building companies. Longitude Capital specializes in making venture growth investments in biotechnolo … $37M under management, investing in breakthrough longevity companies. Longevity Fund companies have collected >$500M in follow-on funding, resulting in the 2018 IPO of the first company dedicated to reversing the diseases of aging. Horizons Ventures is a venture capital firm based in Hong Kong with a focus on disruptive and technology-focused start-ups. For Clinical Study Inquiries, please contact [email protected] For additional information, please contact info@ep
Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America Annual Scientific Meeting 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Releas … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America Annual Scientific Meeting 2025 November 18, 2025 | 4 min read Twitter LinkedIn Facebook Email Print MF-300 is a first-in-class, or … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy August 12, 2020 | 5 min read Twitter LinkedIn Facebook Email Print Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy -- Additionally, E … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 ((+)-Epicatechin) for the Treatment of Duchenne and Becker Muscular Dystrophy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 ((+)-Epicatechin) for the Treatment of Duchenne and Becker Muscular Dystrophy April 14, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biogenes … births. “We are delighted that the data presented on EB 002 supported the FDA’s grant of an orphan-drug designation,” said Russell Cox, Epirium’s chief executive officer. “This is an important milestone for the development of our potential treatment for Becker muscular dystrophy patients, for whom there are no specific treatment options. Our hope is that this designation along with our robust clinical development program will lead to potential new therapies in diseases where … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman December 23, 2024 | 4 min read Twitter LinkedIn Facebook Email Print MF-300 Phase 1 Patient Screening Commencing Expect … g Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of sarcopenia, or age-induced muscle weakness. The first study under this IND will be a Phase 1 randomized, double-blinded, placebo controlled, dose escalation clinical trial of MF-300 in healthy adults. The primary objective of the Phase 1 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Announces First Participants Dosed in Phase 1 Clinical Trial in Healthy Volunteers, Evaluating MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu S … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Announces First Participants Dosed in Phase 1 Clinical Trial in Healthy Volunteers, Evaluating MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia January 30, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Company expects to share preliminary Phase … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Completes Dosing in First-In-Human Phase 1 Clinical Trial Evaluating MF-300, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Completes Dosing in First-In-Human Phase 1 Clinical Trial Evaluating MF-300, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia July 21, 2025 | 2 min read Twitter LinkedIn Facebook Email Print Company expects to share topline results later this Quarter SAN DIEGO-- … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio to Present New MF-300 Clinical and Translational Data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufact … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio to Present New MF-300 Clinical and Translational Data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026 March 12, 2026 | 5 min read Twitter LinkedIn Facebook Email Print MF-300 Phase 1 results demonstrate robust target engagement with no safety concerns identified. SAN … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Raises $85 Million in Series A Financing to Advance Unique Scientific Platform Focused on Restoration of Tissue Bioenergetics and Function - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Epirium Raises $85 Million in Series A Financing to Advance Unique Scientific Platform Focused on Restoration of Tissue Bioenergetics and Function December 18, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Longitude Capital and ARCH Venture Partners Co-lead Financing Together with Bluebird Ventures … Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund Dec. 18, 2019 14:00 UTC SAN FRANCISCO--( BUSINESS WIRE )-- Epirium Bio, Inc. (“Epirium”) formerly, Cardero Therapeutics, Inc., today announced it has raised $85 million in Series A financing provided by Longitude Capital, ARCH Venture Partners, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund. Epirium is a clinical stage biopharmaceutical company dev … “I look forward to leading a very experienced management team as we advance the application of the unique biology we have discovered, which has already produced promising signals of clinical benefit.” Epirium is headed by a seasoned team of industry veterans with decades of experience building and leading clinical and commercial stage companies. The senior leadership team includes: President and Chief Executive Officer Russell Cox, former CEO of Vital Therapies and COO of Jaz … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia January 8, 2026 | 4 min read Twitter LinkedIn Facebook Email Print As with the younger study participants, no safety concerns or dose lim … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics June 22, 2023 | 12 min read Twitter LinkedIn Facebook Email Print Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. (“Spyre”), a privately held bi … ve approximately $220 million in cash or cash equivalents at close: expected to fund operations into 2026 Webcast, June 22, 2023 at 9 a.m. ET AUSTIN, Texas and WALTHAM, Mass. , June 22, 2023 /PRNewswire/ -- Aeglea Biotherapeutics Inc. ("Aeglea") (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform t … best-in-class IBD products through multiple data milestones and are expected to fund operations into 2026. Spyre is the second spinout of Paragon Therapeutics. Spyre was founded to transform the treatment of IBD by pursuing potentially best-in-class long-acting antibodies, rational therapeutic combinations, and precision immunology approaches. Integrating these strategic pillars with deep expertise in antibody engineering and biologics development, Spyre aims to maximize the … nine reduction in the PEACE Phase 3 clinical trial. The Marketing Authorization Application for pegzilarginase is currently under review with the European Medicines Agency. Aeglea has also developed a pipeline of engineered human enzymes that have been explored in preclinical testing, the most advanced of which is for the potential treatment of C
California Biotech, Pharma & Medical Device Company List About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact California Biotech, Pharmaceutical & Life Sciences Companies Order by: Company Name - Location San Diego, CA iNGENu CRO | The FDA-centric CRO HQ’ed in Australia, with global offices (Asia, UK, EU, USA). Delivering high-quality clinical research at a fraction of the cost. Camarillo, CA Curia (formerly AMRI) is a CRO/CDMO providing discovery, development, drug substance and drug product manufacturing for small molecule … La Jolla, CA Proprietary formulations of WNT stem cell activators fur surgical application Arialys Therapeutics La Jolla, CA Therapies for autoimmune neuropsychiatric diseases Aspera Biomedicines La Jolla, CA Space Drug Discovery Azenta Life Sciences La Jolla, CA Automation Products Behavioral Pharma La Jolla, CA Preclinical Lab Services BioSpring La Jolla, CA Manufacturing & Analytical Services CalciMedica La Jolla, CA Small Molecules Cellarcus Biosciences La Jolla, CA Extr … heimer's Cell Marque Rocklin, CA Antibodies, etc. Peninsula Research Associates Rolling Hills Estates, CA Clinical Research Epirium Bio Sacramento, CA Mitochondria Targeting Hand Biomechanics Lab Sacramento, CA Hand Corrective Devices Immuno Concepts Sacramento, CA Diagnostics LabyRx Immuno-Oncology Sacramento, CA Monoclonal Antibody NeuroVision Imaging Sacramento, CA Medical device for retinal autofluorescence Nivagen Sacramento, CA Generics, 505(b)(2) StemCardia Sacramento,
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board | Rice News | News and Media Relations | Rice University Skip to main content Body Rice University News and Media Relations Office of Public Affairs Login Menu Search Form Main Nav < back Current News Featured Stories News Releases Expert Alerts Dateline Rice National Media Relations News Pre-2020 Contact Us Close RICE NEWS > Current News > 2025 Jul. 31, 2025 POSTED IN: RICE NEWS > Current News > 2025 Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board The Rice Biotech Launch Pad , a Housto … he was also awarded the prestigious NGS Integrative Sciences and Technology PhD scholarship. Ng is the 16th member of the Launch Pad’s external advisory board. The other members are David Allison, managing director at Westlake BioPartners; Jason Bock, founder and CEO of CTMC; Albert Cha, managing partner of Frazier Life Sciences; Rima Chakrabarti, partner at KdT Ventures and CEO of Sentinel BioTherapeutics; John Flavin, founder and CEO of Portal Innovations, co-founder and ch
Epirium Bio - Broadview Ventures About Us Team Portfolio Press Epirium Bio Epirium is a clinical stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue regeneration, potentially resulting in novel and clinically significant therapeutic approaches to currently intractable neuromuscular and neurodegenerative diseases, including primary and secondary cardiomyopathies. The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimu … Suite 1902 Boston, MA 02110 617-459-4686 Email Us About Us Team Portfolio Press Submit Proposal Submit Proposal © 2026 Broadview Ventures. All Rights Reserved. Privacy Policy Boston Web Design
Can this San Diego startup mimic exercise and fasting with a pill? Epirium raises $85M to find out – San Diego Union-Tribune Skip to content All Sections 65°F Friday, June 26th 2026 e-Edition Home Page World Cup 2026 About Us About Us Our Journalism Community Advisory Board Contact the Newsroom eNewspaper The San Diego Union-Tribune Carmel Valley News Del Mar Times Encinitas Advocate La Jolla Light PB Monthly Point Loma OB Monthly Poway News Chieftain Ramona Sentinel Rancho Bernardo News Rancho Santa Fe Review Solana Beach Sun Columnists Nick Canepa Lisa Deaderick Tom Krasovic Bryce … cing, which closed in December. There’s also an investor called Longevity Fund, a group focused on extending human life. Epirium employs 10 people today at its La Jolla headquarters and plans to add 40 more positions within 12 months. The new jobs will span several departments, from clinical development and operations to office staff. Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Print (Opens in new window) Print Email a
Paul Berns - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact > Paul Berns Managing Director Paul L. Berns is a Managing Director with ARCH Venture Partners. Mr. Berns has been a member of ARCH Venture Partners since August 2018 and became a Managing Director in 2021. Mr. Berns is the Co-founder and Executive Chairman of both Tenvie Therapeutics and Ollin Biosciences. Mr. Berns was also the Co-founder and Chairman of the Board of Directors for H
Epirium's MF-300 shows promise in Phase 1 trial for sarcopenia | Alexander Casdin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … rs 9mo Report this post MAIA is thrilled to have been awarded a prestigious NIH grant to support the expansion of our Phase 2 trial in the clinical development of ateganosine. This achievement marks a major milestone and reflects the dedication, collaboration, and hard work of everyone involved. Ateganosine represents a potential solution for the significant unmet clinical need in third-line NSCLC, where no established standard of care exists and where the overall survival ou … sis development, it will significantly aid future drug development.” During the application process in ODIN, Novo Nordisk proactively reached out to the academic team to express their interest in the project. Together with the other industry partner, they helped shape the final proposal – ensuring strong relevance and engagement from both sides. The FibroCard project is a great example of how ODIN projects can start as academic ideas and grow into collaborations that are valu
Portfolio – Broadview Ventures About Us Team Portfolio Press All Category Medtech BioPharma Status Active Exited BioPharma Reverse Merger (Nasdaq: Capr) IPO (Nasdaq: Lyra) Reverse Merger (Nasdaq: VRDN) Acquired by Mesoblast Out-license / Exited to Gossamer Acquired by Biogen Acquired by Rocket Pharma (Nasdaq: RCKT) × Aeromics is a clinical stage drug development company developing Aquaporin inhibitors for the treatment of cerebral edema in stroke, based on pioneering discoveries by Dr. Peter Agre (2003 Nobel Prize in Chemistry). Cerebral edema is predictive of patient outcome in is … ic company focused on pharmacological treatment of obesity employing intra-oral application of naturally occurring satiety hormones to induce early fullness, leading to weight loss. Targeting a unique and recently discovered direct neural pathway between the tongue and brain, Gila is developing formulations that when applied to the tongue prior to meals directly stimulates the brain’s satiety centers intended to reduce food intake without any systemic exposure. Gila, based in … ecause of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child. We plan to commercialize our products through strategic partners as we expand indications to benefit all individuals with diabetes. Go to website: https://mellitushealth.com × miRagen Therapeutics, Inc. , is a clinical-stage biopharmaceutical comp … amer Bio (NASDAQ:GOSS) has licensed the PAH program (GB002) and will manage and fund the development through regulatory approval. Go to website: http://pulmokine.net/ × Remedy Pharmaceuticals, Inc. is a privately-held, late clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system edema. Remedy is developing CIRARA for the improvement of functional outcomes by reducing the formation o … Suite 1902 Boston, MA 02110 617-459-4686 Email Us About Us Team Portfolio Press Submit Proposal Submit Proposal © 2026 Broadview Ventures. All Rights Reserved. Privacy Policy Boston Web Design
Epirium Bio Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Tu … tners , Adams Street , Longitude Capital , Sutter Hill Ventures , The Longevity Fund , and Vertex Ventures HC $XXM 0 FY undefined 13 5/22/2015 Unattributed VC $XXM Subscribe to see more $XXM 0 FY undefined 0 10/16/2014 Unattributed $XXM Subscribe to see more $XXM 0 FY undefined 10 10/14/2011 Series A $XXM Subscribe to see more $XXM 0 FY undefined 10 Other Investors Subscribe to see more $XXM 0 FY undefined 10 Date 12/18/2019 5/22/2015 10/16/2014 10/14/2011 Round Series A - II … tners , Adams Street , Longitude Capital , Sutter Hill Ventures , The Longevity Fund , and Vertex Ventures HC Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined Sources 13 0 10 10 10 Learn more by requesting a demo Epirium Bio Investors 11 Investors Epirium Bio has 11 investors . The Longevity Fund invested in Epirium Bio&# … g Investor Rounds Board Seats Type Location 12/18/2019 12/18/2019 The Longevity Fund 1 Series A - II Venture Capital California 12/18/2019 12/18/2019 ARCH Venture Partners 1 Series A - II Venture Capital Illinois 12/18/2019 12/18/2019 Longitude Capital 1 Series A - II Venture Capital California 00/00/0000 00/00/0000 Sutter Hill Ventures Subscribe to see more Private Equity California 00/00/0000 00/00/0000 Vertex Ventures HC Subscribe to see more Venture Capital California Fir … g 12/18/2019 12/18/2019 12/18/2019 00/00/0000 00/00/0000 Investor The Longevity Fund ARCH Venture Partners Longitude Capital Sutter Hill Ventures Vertex Ventures HC Rounds 1 Series A - II 1 Series A - II 1 Series A - II Subscribe to see more Subscribe to see more Board Seats Type Venture Capital Venture Capital Venture Capital Private Equity Vent
Posters, Presentations and Publications | Epirium Bio Posters, Presentations and Publications – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Posters, Presentations and Publications Posters and Presentations DDW 2026: Novel Oral Inhibitors of 15-PGDH Improve Disease Outcomes in DSS Mouse Models of Colitis ICFSR 2026: Bridging Preclin
Press Releases | Epirium Bio Press Releases – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Press Releases 2026 05/05/26 – Epirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week 2026 03/12/26 – Epirium Bio to Present New MF-300 Clinical and Tran … of Sarcopenia 2024 12/23/24 – Epirium Bio Announces FDA Clearance of IND Application for MF-300 and Appointment of Alex Casdin as New CEO and Russell Cox as Executive Chairman 11/13/24 – Epirium Bio Presented Late-Breaking Preclinical Data of MF-300 (15-PGDH Enzyme Inhibitor) at the Gerontological Society of America Annual Scientific Meeting 2024 Archived Press Releases For Clinical Study Inquiries, please contact [email protected] For additional informat
About Us | Epirium Bio About Us – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact About Us Epirium Bio is a biopharmaceutical company that has identified and established an IP-protected platform of orally bioavailable small molecules that leverages the potential of PGE-2 signaling to restore tissue homeostasis, resolving aberrant infla
Pipeline | Epirium Bio Pipeline – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Pipeline Musculoskeletal Inflammatory / Fibrotic Therapeutic Area 15-PGDH INHIBITOR (Oral) PRECLINICAL IND ENABLING PHASE 1 PHASE 2 Sarcopenia Potential label expansion: Sarcopenic obesity MF-300 Phase 2b Upcoming Milestones: ✓ Phase 1 completed Q4 ’25 ✓ … g Milestones: ✓ Phase 1 completed Q4 ’25 ✓ FDA End-of-phase 1 Q1 ’26 Fast track application Q2 ’26 Phase 2b FPI Mid ’26 Phase 2b TLR H2 ’27 Osteoporosis* MF-300 IND ready Spinal Muscular Atrophy MF-300 IND ready Preclinical Proof of Concept Achieved IBD – Ulcerative Colitis, Crohn’s Disease MF-1305 MF-300 Idiopathic Pulmonary Fibrosis MF-300 *Human proof of concept (bone biomarkers & bone mineral density) to be generated in Sarcopenia Phase 2b study Disease Target S
Management Team & Advisors | Epirium Bio Management Team & Advisors – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Management Team & Advisors Management Team Alexander Casdin Chief Executive Officer Alexander Casdin Chief Executive Officer Alex is Epirium’s Chief Executive Officer, and a member of the board of directo … olio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the D
Epirium Bio Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Epirium Bio Teams Epirium Bio Save Saved San Diego 25 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech Epirium Bio is a clinical stage bio pharmaceutical company. Epirium Bio Offices OnSite Workspace Employees work from physical offices. Typical time on-site: San Diego, California, USA Companies Jobs Tracker Articles More Join Log In Tech Jobs Companies Articles
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
BioCentury - Casdin to succeed Cox at Epirium This Edition ARTICLE | Management Tracks Casdin to succeed Cox at Epirium Plus: van Tilburg takes the helm at Renovaro and updates from Medicilon, Applied, Neurocentrx and more By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst December 31, 2024 11:39 PM UTC As San Diego-based Epirium Bio Inc. becomes a clinical company, it is elevating COO Alex Casdin to CEO on Jan. 1, succeeding Russell Cox, who will become executive chair. Epirium said FDA has cleared an IND for MF-300, an orally administered, 15-hydroxyprostaglandin dehydr … e BV. Van Tilburg recently retired as the director of the Dutch National Growth Fund... BCIQ Company Profiles Applied Therapeutics Inc. Asklepion Pharmaceuticals LLC Epirium Bio Inc. Marea Therapeutics Inc. Neurocentrx Pharma Ltd. Procaps Group S.A. Renovaro Inc. (pre-merger) View more ▼ BCIQ Company Profiles Applied Therapeutics Inc. Asklepion Pharmaceuticals LLC Epirium Bio Inc. Marea Therapeutics Inc. Neurocentrx Pharma Ltd. Procaps Group S.A. Renovaro Inc. (pre-merger) Vi
%PDF-1.7 %���� 1 0 obj >/Metadata 123 0 R/ViewerPreferences 124 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]Kk$����mPM�+ D���66^��1>,>,�zO^��?8#�]�QjwGˆ�4-eDfd ��o�|�����/y���o�?��!q���iv7�i>|�{��o��?�'������O_��� ~u��__���9��?}�t8w: z��=�� }n� ��9�r4�OG��~��X��B)�>G�(��i�EU��rtωBgĉ���'N✙��������ǵ���������D�xHRb��/>ޕ��9�E � z�28���y�}9E� '�g.�f�G��H������S�����BH�ʵ�����5Y�+�d[j!No �G��$���3Ǯ/o�'�)x�
Careers | Epirium Bio Careers – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Careers There are no current job openings Epirium Bio and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. We do not ask candidates to purchase anything through us or to provi
Portfolio ABOUT PORTFOLIO NEWS CONTACT Portfolio Epirium Bio Mitochondrial Biogenesis Epirium Bio is developing a new class of therapeutics that stimulates muscle growth and strength as well as benefiting biogenesis in other tissues. The Company has clinical data in several degenerative muscle disease indications including Becker’s Muscular Dystrophy. Founded by George Schreiner MD PhD and Sundeep Dugar PhD. Series A Investor and Board member Forty Seven Immuno-Oncology Forty Seven developed an antibody against CD47, a “Don’t Eat Me” signal that regulates immune activity against many cancers.
Epirium Bio Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Epirium Bio is a biopharmaceutical company that has identified and established an IP-protected platform of orally bioavailable small molecules that leverages the potential of PGE-2 signaling to restore tissue homeostasis, resolving aberrant inflammation, stimulating regeneration, an
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Leadership | Epirium Bio Leadership – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Leadership Management Team and Consultants Board of Directors Advisors Alexander Casdin Chief Executive Officer Alexander Casdin Chief Executive Officer Alex is Epirium’s Chief Executive Officer, and a member of the board of directors. He previously s … olio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the D … nt practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund, and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna … olio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the D
Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia January 28, 2026 | 4 min read Twitter LinkedIn Facebook Email Print - Alignment gained on Phase 2b inclusion/exclusion criteria, primary and secondary endpoin … elated sarcopenia in the second half of 2026. The Company also plans to file an application for Fast Track Designation which, if accepted, will allow greater access to FDA interaction during MF-300 development for sarcopenia and enable priority review. “We are pleased with the positive outcome of our End-of-Phase 1 meeting with the FDA, which provided constructive guidance on our development strategy for MF-300 in sarcopenia,” said Alex Casdin, Chief Executive Officer of Epir … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Board of Directors | Epirium Bio Board of Directors – Epirium Bio Toggle navigation About Us Our Science Science Pipeline MF-300: Sarcopenia Posters, Presentations and Publications Leadership Management Team & Advisors Board of Directors Sarcopenia Development Council Scientific Advisors Investors Investors Presentations Press Releases Careers Contact Board of Directors Russell J. Cox Executive Chairman Russell J. Cox Executive Chairman Russell is currently the Executive Chairman at Epirium Bio. Previously he served as President and Chief Executive Officer. Prior to Epirium, Russell … nt practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund, and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna … olio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the D
Largest And Global Sovereign Wealth Fund Institute | SWFI SWF Summit Events Demo Login Services Subscription Membership Datafeeds/API Public Fund Monitor Advertising Consulting Quarterly News Policy Deals Europe Asia Real Estate Alternatives Real Assets Public Pension Private Equity Energy Crypto Infrastructure Fund Rankings SWF Public Pension Bank Endowment Central Bank Superannuation Foundation Manager Rankings Asset Manager Bank Financial Holding Company Crypto Wealth Manager Hedge Fund Manager Profiles SWF Public Pension Superannuation Endowment Central Bank State Owned Manager Family Offi … ice Afore Transactions Listed Equity Unlisted Equity Real Estate Private Equity Fund Real Estate Fund Credit Fund Infrastructure Active Equities RFPs Active Equities Active Fixed Income Private Equity Fund Real Estate Fund Credit Fund Real Estate Hedge Fund Consultant Events Demo Login Book a Demo Public Fund Monitor Pages Services Subscription Membership Datafeeds/API Public Fund Monitor Advertising Consulting Quarterly Fund Rankings Fund Manager Rankings Events News Researc … any Cannabis Company Central Bank Company Corporate Pension Credit Union Crypto Fund Manager Development Bank Endowment Export Credit Agency Family Enterprise Family Office Family Trust Finance Ministry Financial Holding Company Foundation Fund Government Government Bank Government Fund Healthcare Foundation Hedge Fund Manager Holding Company Insurance Investment Consultant Investment Trust Investor Joint Venture Land Bank Law Firm Media Company National Oil Company Native Am … t Venture Land Bank Law Firm Media Company National Oil Company Native American Fund Nonbank Lender Pension People Pharmaceutical Company Public Pension Real Estate Company Real Estate Investment Trust Retailer Safety Pension Sovereign Wealth Fund Special Purpose Entity State Owned Enterprise Superannuation Supranational Entity Trading Company Venture Capital Firm Wealth Manager Transactions All Transactions Active Equities Active Fixed Income Business Development Company Con … Active Fixed Income Business Development Company Consultant Convertible Credit Fund Cryptocurarencies Derivative ESG Fund Fixed Income Fund Hedge Fund Infrastructure Infrastructure Fund Insurance Listed Equity Multi-Asset Passive Equities Passive Fixed Income Private Equity Fund Real Asset Fund Real Estate Real Estate Fund Service Provider Smart